Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo Holdings
Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces that it has successfully closed an oversubscribed €45M Series B financing round. The equity financing was co-led by new US-based investors Canaan and Alpha Wave and with participation by the Global BioAccess Fund, as well as existing investor Novo Holdings.
